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ABSTRACT
Objectives: This study examined the adherence to opioid therapy in patients with chronic noncancer pain (CNCP). The prevalence of opioid use and 
pain scores was also explored.
Methods: This cross-sectional study was conducted among patients with noncancer pain attending a pain clinic at a tertiary hospital in Malaysia 
from August 2016 to February 2017. All patients prescribed with any of the five available opioids (morphine, oxycodone, fentanyl, buprenorphine, 
and dihydrocodeine) were included in the study, and their medical and prescription records were assessed for further information on opioid use 
such as the type of opioid, dose, frequency, and duration. The prevalence of opioid use was calculated by dividing the number of opioid users and the 
total number of patients attending the pain clinic during the study. Adherence was calculated for patients with long-term opioid therapy (>90 days/
year) and measured using the medication possession ratio (MPR). This was derived by sum up the total days covered with medication in the last 
365 days; and then divide that by the total days, the medication was prescribed over the same period. A cutoff point of 80% or more was considered 
as adherence. The pain intensity score was assessed through a numerical scale from 0 (no pain) to 10 (worst possible pain) at four different points 
(now, on average, least in the last 24 h, and worst in the last 24 h).
Results: A total of 555 patients with various noncancer pain conditions attended the pain clinic during the study. The prevalence of opioid use 
among these patients was 13.5% (n=74/555). Of these, 24.3% (n=18/74) of patients using opioids for long term (>90 days) and were included in the 
adherence measure. 78% (n=14/18) of these long-term opioid users were adherent to opioid therapy with a reported MPR >80%. 22% (n=4/18) of 
patients showed nonadherence to opioid therapy with a reported MPR <80%. The mean pain score for both adherent and nonadherent groups was 
5/10, and there was no statistical difference between the two groups.
Conclusion: The preliminary results of this study demonstrated that the majority of patients with chronic opioid use adhered to their prescribed 
opioids. The prevalence of opioid use among patients with noncancer pain was low, and the number of patients using opioid for the long term was 
~20% which is similar to the finding from the previous study. The future research is required to evaluate the clinical outcomes in patients with CNCP 
using opioid for long term particularly in nonadherent patients.
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INTRODUCTION
The pain is defined by The International Association for the Study of 
Pain as “an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage or described regarding such 
damage [1].” Pain is one of the most prevalent health problems [2] 
and is considered the fifth vital sign [3]. Most of the health conditions 
(such as cancer, rheumatoid arthritis, fibromyalgia and postherpetic 
neuralgia, and chronic back pain) are associated with pain in which 
pain control remains the top priority for these health conditions. 
Chronic pain can be defined as the pain that persists for 3 months, 
or more and\or exceeds the healing time required for the damaged 
tissue [2]. This type of pain is considered among the leading reasons 
for increasing the healthcare services demand and cost, and perhaps 
most importantly, reducing the patients’ quality of life [4]. Pain relief 
remains the cornerstone of the treatment for pain especially when 
there is no cure for the underlying diseases [4]. Opioids are strong 
analgesics that have been used for centuries for the treatment of pain. 
In the last few decades, the use of opioid has dramatically increased 
in managing chronic noncancer pain (CNCP), despite the fact that the 
use in this CNCP condition is controversial as the available evidence 
is limited to short-term efficacy and side effects [5]. A number of 
concerns are raised regarding the long-term use of opioids in CNCP 
which include increased risks of opioid tolerance, abuse, addiction, 
and opioid overdose death. It is reported that in the United States, 
the opioid overdose death has increased four-fold in the last 
10 years [6]. Adherence to opioid treatment is important in achieving 
the treatment goals of relieving pain, improving quality of life, and 
preventing the unwanted consequences such as addiction and abuse 
or misuse. Adherence is defined as “the extent to which a patient 
acts in accordance with the prescribed interval and dose of a dosing 
regimen[7],” or it also can be defined as the “active, voluntary, and 
collaborative involvement of the patient in a mutually acceptable 
course of behavior to produce a therapeutic result [8].” Poor adherence 
is accompanied by the increase in morbidity and mortality, treatment 
cost, and worsening in the overall health outcomes [9,10]. To date, 
there is limited data available on the adherence to opioid therapy 
in CNCP patients in Malaysia. As such, this study was prompted to 
investigate the adherence to opioids in patients with CNCP. The 
prevalence of opioid use and pain intensity score was also evaluated 
and correlated with the adherence measure.
3rd International Conference on Pharmacy and Pharmaceutical Sciences (ICPPS 2018)
Research Article
Asian J Pharm Clin Res, Vol 11, Special issue 3, 2018
 Mizher et al. 
 3rd International Conference on Pharmacy and Pharmaceutical Science 2018 5
METHODS
Study type
This was a retrospective cross-sectional clinical study conducted at a 
pain clinic of a tertiary hospital setting in Malaysia. The approval from 
the Medical Research Ethical Committee, Ministry of Health Malaysia 
was obtained before conducting the study. Only patients, who gave 
consent form, were included in the study.
Study design and data sources
Patient’s recruitment was carried out between August 2016 and 
February 2017 during their scheduled visit to pain the clinic. The 
patients were recruited into the study if they met the following 
inclusion criteria: A current opioid user taking one or more of the 
opioids included in the study (morphine, dihydrocodeine, oxycodone, 
oxycodone/naloxone, fentanyl, and buprenorphine), diagnosed with 
a noncancer pain, and age of 18 years or older. The patients were 
excluded if they have a history of opioid substance abuse or received 
injectable opioids as they are considered in-patients. Cancer pain 
patients were also excluded from the study. The included patients were 
further categorized into short-term and long-term opioid users based 
on the days of opioid use. The long-term opioid use was defined as 
using prescribed opioid for more than 90 days in the last 365 days, and 
this group of patients was included in the adherence measures and final 
analysis.
Prescriptions and medical records of long-term opioid users included 
in the study were reviewed. Data included the name and opioid type, 
date dispensed, quantity dispensed, and total days of drug supply 
were extracted from the prescription records. Patients’ characteristics, 
including age, gender, and diagnosis, were also recorded.
Outcome measures
Prevalence
The prevalence of opioid use among noncancer pain patients was 
calculated by counting the total number of patients using opioid therapy 
and then dividing that by the total number of pain patients attending 
the clinic during the study.
Adherence measure
Adherence was calculated among the long-term opioid users using 
the medication possession ratio (MPR). MPR is generally expressed 
as the proportion of days in which the medication is supplied over a 
specified period [11]. In the present study, once a long-term patient 
was identified, all their previous pharmacy and medical records on 
opioid use were revised. Data during the observation period (the last 
365 or subsequent for patients with <365 days use) days were included 
in the calculation. The total days of drug supply were measured by 
counting the days for all prescriptions within the observation period. 
The following formula was used to calculate the MPR in this study [12]:
 Total days of drug supply*
Total days in observation peri
MPR=
od**
*The total days of drug supply was measured by calculating the period 
(in days) for all prescriptions within the observation period. **The 
total days in the observation period is considered as the previous year 
(365 days or subsequent) from the end date.
The end date was the date when patients were seen at the pain clinic 
and assessed for their pain level. The observation period is the sum-up 
of the days in which the patient is covered with an opioid prescription 
between the index date until the end date. The index date is the first 
day of opioid prescription in the last 365 days. In other words, the 
previous 365 days are the observation period for the patients who were 
taking opioid for 365 days or more, and the total days of opioid usage 
is considered for patients with <365 days usage. For example, both 
patients A and B met the inclusion criteria, while patient A was under 
opioid for 2 years, and patient B for 200 days, then the observation 
period for both patients will be 365 and 200 days, respectively.
A percentage value of 80% or more for MPR is considered as adherent, 
and a value of <80% as nonadherent [11]. When the prescription was 
dispensed before the stipulated date, the overlapping days between 
prescription refills were excluded from the observation period to avoid 
adherence >100% [13].
Pain intensity score
The pain score was evaluated using a numerical pain scale from 0 to 10. 
Each patient was asked about their pain level at four different aspects 
(now, worst in last 24 h, least in the last 24 h, and pain on average) 
based on a verbal scale from 0 to 10, where 0 represents no pain, and 10 
represents the worst imaginable pain [14]. Data were expressed as mean 
± (standard deviation [SD]) and analyzed using the Student’s t-test for 
the comparison between adherent and nonadherent. Differences were 
considered statistically significant, if p<0.05.
RESULTS
Study subjects
A total of 555 patients attended the pain clinic during the study, and 
they were diagnosed with various pain conditions such as neuropathic 
pain as fibromyalgia and diabetic neuropathy, or inflammatory as 
osteoarthritis or other musculoskeletal diseases (Fig. 1).
Of 555 patients, 74 patients were using the opioid therapy and the 
prevalence of opioid use among pain patients for was 13.5%. Of the 
74 patients using opioids, a total of 18 patients were long-term opioid 
users and included in the analysis. Details of patients’ characteristics 
are summarized in Table 1. There were 61% (n=11/18) of males and 
39% (n=7/18) of females included in this study. The mean age was 53.2 
years old ± SD (11.3). The main diagnosis was back pain 33% (n=6/18), 
followed by bilateral hip pain 11% (n=2/18).
Table 1: Demographic details of long‑term opioid 
patients (n=18)














Back pain 6 (33)
Bilateral hip pain 2 (11)
Fibromyalgia 1 (5.5)
Postsurgical pain syndrome 1 (5.5)
Chronic knee pain 1 (5.5)
Sensory neuropathy 1 (5.5)
Neuropathic 1 (5.5)
Brachial plexus injury with neuropathic pain 1 (5.5)
Postherpetic neuralgia 1 (5.5)
Diabetic neuropathy 1 (5.5)
Chronic venous insufficiency. 1 (5.5)
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The most prescribed opioid was dihydrocodeine 61% (n=11/18), 
followed by oxycodone 22% (n=4/18), and then morphine, fentanyl, 
and buprenorphine 5.5% (n=1/18) for each of them.
Adherence measurement using MPR
Of the 18 patients, 14 patients (77.8%) adhered to their prescribed 
regimen as their MPR value was 80% or more. Four patients (22.2%) 
showed nonadherence with MPR value of <80%. The mean total days 
covered for adherent patients was 261 days compared with 151 for 
the nonadherent group, while the mean total days prescribed for the 
adherent and nonadherent groups
were 282 and 234 days, respectively. The mean MPR for the adherent 
was 93% and for the nonadherent was 64% (Fig. 2).
Pain intensity score
As per Fig. 3, both adherent and nonadherent groups reported the mean 
pain score as five points on the scale as the average pain. Similarly, both 
groups ranked seven points for the worst pain over the last 24h. Pain 
now and the least pain in the adherent group were 4 and 3 which are 
slightly lesser compared with nonadherent whose pain was 5 and 4, 
respectively. There was no statistical difference between the adherent 
and the nonadherent group at the four points.
DISCUSSION
The finding from this study demonstrated that the majority of patients 
with long-term opioid therapy for CNCP were adherent to their opioid 
therapy. The nonadherence to opioid therapy was shown in 22% of 
patients. This finding is consistent with previous studies that reported 
rates of nonadherence in chronic pain patients from 8% to 62% [15,16]. 
Among opioid users, nonadherence was reported from as low as 2% 
to 53%, the wide range was reported mainly due to the definition 
of adherence, as some studies considered nonadherence based on 
medication underuse only, while some other authors measured 
medication under or overuse as nonadherence [17-19]. Factors, such 
as increasing frequency of dosing and pain intensity, were reported 
positively correlated with poor adherence. Other factors, such as 
concern about addiction and side effects, were also related to affect 
patient adherence to opioid therapy [19]. To ensure patients adherent 
to the opioid therapy and to achieve the treatment goals, all the related 
factors affecting the adherence need to be improved. The present study 
was also demonstrated that the prevalence of opioid use among patients 
with noncancer pain was 13.5%. The prevalence from this study is 
low as compared with a recent study of long-term therapy in CNCP 
conducted in a pain clinic in Germany with a prevalence of 51% [20]. 
The big difference could be justified because the opioid use is more 
common in their population. A low prevalence in the present study 
may also be explained by the total opioid consumption in Malaysia is 
much lower (0.3643 DDD/1000 population/day) compared to other 
Fig. 1: Study subject flowchart
Fig. 2: Days cover with opioids in adherent and nonadherent 
groups
Fig. 3: Comparison of pain scores between adherent and 
nonadherent groups
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countries such as Australia and Nordic countries (9 and 18 DDD/1000 
population/day, respectively) [21].
The low prevalence of opioid use in this current study may also be 
associated with the low prevalence of chronic pain patients in Malaysia 
(7%) [22] as compared to other countries such as in the developed 
countries (10–50%) [4] Europe (20%) [23] and UK (35.0% to 51.3% [24]. 
Patients, undergoing opioid therapy, are assumed to report lower pain 
scores. Thus, uncontrolled pain is an indication of poor adherence, and 
physicians may need to draw attention to the patients’ compliance with 
their therapeutic plan. In the present study, pain scores were not different 
among the adherent and nonadherent groups, and this could be due to 
disease progression or other related problems to opioid such as opioid 
tolerance and opioid induced-hyperalgesia. Thus, knowing that a patient 
is an adherent to their opioid regime while still reporting a high pain 
score will help the physician to investigate these other possibilities. The 
limitation of the study includes the fact that MPR is a measure of adherence 
whereas MPR estimates only the days’ covered with medication in hand, 
while in fact; there is no guarantee whether the patient followed or not 
the time and dosing regimen by the physician [25]. The findings from this 
study give us a sight about the adherence and the prevalence of opioid use 
among noncancer pain patients. However, these results should be used 
with caution due to the limited sample size used which represents the 
studied site, and may not reflect the actual community.
CONCLUSION
Based on our findings, the majority of the patients were adherent 
with their opioid therapy; however, their pain score was not different 
from the nonadherent patients. This could be one of the factors 
related to medication overuse and subsequently could lead to other 
complications such as abuse and opioid overdose death. However, pain 
score is reported based on the patient report only which considered 
a subjective measure. As such, the calculation of adherence using the 
MPR and link that with some other objective measures will be more 
useful to help us to understand the underlying causes contributing to 
the pain scores. The future research is required to investigate factors 
that likely affect the adherence to correlate adherence with the opioid 
dose and to examine the clinical outcomes. Such a study should be 
conducted in a larger sample size.
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